BRAF and cancer: BRAF V600E mutation encodes a constitutively activated B-RAF serine/threonine kinase that leads to a chronic hyperactivation of the RAS/RAF/MEK/ERK signaling pathway, driving oncogenesis in about 7% of human cancers (3, 15–18).